News & Insights on AgentCures

Agentic AI in Drug Discovery: What Agents Actually Do

Sun, 15 Feb 2026 00:00:00 +0000

The lab meeting starts in an hour. Your team has a table of compounds, results from several experiments, and a folder of papers. You want to decide which candidates deserve more work. First, someone has to check the records, compare the evidence, and explain what is still missing.

An AI assistant can help discuss that task. An agent can also work through parts of it: open the available records, run an analysis, notice a problem, and change its next step. That ability to connect actions is what makes agentic AI interesting for research.

Pharma as Code: Keeping Drug Research in Version Control

Thu, 12 Feb 2026 00:00:00 +0000

A report says twenty-four compounds were tested. A revised spreadsheet contains twenty-two usable results. The scientist who made the correction knows why, but the explanation is in a message that the report’s author never saw.

This is a familiar research problem: files change independently, and the decision loses contact with the evidence. Version control helps by recording related changes together and making them available for review.

“Pharma as code” applies that discipline to a research program’s protocols, analysis methods, structured records, and documents. The aim is to make a scientific decision traceable from its source to the version someone actually read.

AI in Drug Discovery: How It Works, With Real Examples

Tue, 10 Feb 2026 00:00:00 +0000

Imagine you have a promising idea for treating a disease and enough lab time to test only a handful of molecules. There are far more possibilities than you can afford to investigate. Which ones should you make first? What would you need to learn before moving forward?

That is where AI can help. It gives researchers ways to compare possibilities, propose new molecular structures, and choose experiments that could settle an important question. The result might be a better candidate. It might also be an early reason to stop pursuing a bad idea.

Autonomous Labs: How AI Learns From the Next Experiment

Thu, 05 Feb 2026 00:00:00 +0000

A robot can run the same assay a thousand times and still leave the hardest question unanswered: what should we test next?

An autonomous laboratory connects the result of one experiment to the choice of another. Software proposes a test, equipment carries it out, and the new data changes the next proposal. The useful part is that feedback. Running faster helps only if the results support better decisions.

For drug discovery, this could mean learning which chemical change improves a molecule, which assay needs troubleshooting, or when a promising idea has stopped making sense.

Protein Structures in Drug Design: Explore the Shape, Check the Evidence

Wed, 28 Jan 2026 00:00:00 +0000

A protein structure turns a chain of amino acids into something a researcher can inspect: folds, surfaces, cavities, and possible sites of interaction. That can make a molecular design question much more specific.

Instead of asking only whether a compound affects a protein, researchers can ask which part of the molecule might contact which residues, whether there is room for a chemical change, and how a related protein might differ.

AI in Clinical Trial Design: Ask a Better Question Before Enrolling

Tue, 20 Jan 2026 00:00:00 +0000

A trial can collect excellent data and still leave an important question unanswered. It might measure an endpoint that matters little to patients, enroll people unlike those expected to use the treatment, or be too small to distinguish a useful effect from noise.

AI can help teams explore these choices before enrollment. It can organize prior evidence, compare patient characteristics, and support models that simulate possible outcomes. Its contribution depends on whether the question, assumptions, and comparison are clear.

Generative AI for Drug Design: From New Molecules to Testable Ideas

Thu, 15 Jan 2026 00:00:00 +0000

Suppose a research team has a molecule with promising activity against a protein. The next design brief is specific: keep the features that seem important for that activity, explore changes that might improve solubility, and propose structures the team could realistically make.

Generative AI can help turn that brief into molecular proposals. The interesting work starts when the team asks which proposals deserve an experiment, and why.

A generated molecule is a design idea with questions attached. Its value depends on whether the structure makes chemical sense, whether it can be made, and what evidence would support developing it further.

AI and IND Documentation: From Research Evidence to a Reviewable Draft

Thu, 08 Jan 2026 00:00:00 +0000

A polished paragraph is easy to generate. Establishing that every number in it comes from the right study is much harder.

That is the central challenge for AI-assisted regulatory writing. An Investigational New Drug application, or IND, brings together evidence supporting a proposed clinical investigation in the United States. The documents must tell a consistent story about the product, the available studies, and the planned research.

AI can help assemble and check that story. Its most useful output is a draft whose statements can be verified, whose gaps remain visible, and whose revisions can be reviewed.

Multi-Target Drug Design: Why More Targets Need a Better Rationale

Sun, 28 Dec 2025 00:00:00 +0000

A molecule that interacts with five proteins is not automatically more useful than one that interacts with a single protein. Some interactions may help. Others may do nothing relevant or introduce harm.

Multi-target drug design starts with a more specific question: which activities need to occur together, in which tissue, and at what exposure? AI can help explore candidate answers. The biological rationale and the balance between those activities still need experimental support.

Building an AI Biotech: What a Useful Platform Should Prove

Thu, 18 Dec 2025 00:00:00 +0000

An AI biotech can generate thousands of molecular ideas before lunch. That says little about whether any are worth making.

The more revealing question is what happens after an idea meets an experiment. Can the team identify why a prediction failed, improve the method, and use the lesson on another program? Can it show that this process makes a research decision better?

Building around AI means designing a company that can answer those questions repeatedly. The models are one part of that organization. Its data practices, experimental capabilities, and review habits matter just as much.

AI and Precision Medicine: Which Patient Differences Actually Matter?

Wed, 10 Dec 2025 00:00:00 +0000

Two people can share a diagnosis and have different disease drivers, histories, and responses to treatment. Precision medicine tries to make those differences useful for a specific decision.

AI can help connect molecular measurements with clinical records and outcomes. But finding a pattern is only the start. The harder question is whether that pattern identifies a treatment choice that improves outcomes for the people who will use it.

A useful patient model needs a clearly defined job. Predicting who will do poorly is different from predicting who will benefit more from a particular treatment.

Can AI Make Drug Development Cheaper? Follow the Costs

Mon, 01 Dec 2025 00:00:00 +0000

Imagine a research team with enough money to investigate several treatment ideas, but too little to pursue all of them. The team considers an AI tool that could help choose which ideas to test. Running predictions might cost less than making and testing every candidate. The question is whether those predictions lead to better choices.

That sounds like a saving. Whether it becomes one depends on what happens next. Does the team avoid work that would have failed? Spend more time checking predictions? Reject an idea that would have worked? Those outcomes have different economic consequences.

ADMET Explained: Why Strong Binding Is Only the Beginning

Thu, 20 Nov 2025 00:00:00 +0000

A molecule looks promising in an experiment. It binds to the intended protein, and a small chemical change makes that binding stronger. The team has a reason to be excited. It also has a new set of questions: can the molecule reach that protein in the body, stay there long enough, and avoid unacceptable harm?

Those questions are the territory of ADMET: absorption, distribution, metabolism, excretion, and toxicity. They help explain why a good result in a binding assay is an early step in developing a medicine.

AI and Rare Diseases: Making Small Research Programs More Informative

Mon, 10 Nov 2025 00:00:00 +0000

A rare disease program may begin with a known genetic change, a committed patient community, and very little reliable information about how the condition progresses. A clear starting point can coexist with large gaps in the evidence.

AI can help organize scattered observations, compare treatment hypotheses, and reduce repeated computational work. It cannot create missing clinical history or make a small, biased dataset representative by analyzing it more intensively.

The useful question is where these tools can help a team learn more from the research it can realistically do.